Moreover, in recent melanoma clinical trials, neoantigen vaccination induces CD4+ T cell responses and improves patient survival (NCT02035956, n = 15) [145], (NCT02287428, n = 56) [146,147]. The gene discussed is CD4; the disease is melanoma.